Table 3.

Summary of ongoing immunotherapy trials for the treatment of acral and mucosal melanoma.

Trial identifier	Phase	Target population	n	Regimens	Setting	Location
NCT03820986 (LEAP-003)	III	Cutaneous, acral, and mucosal melanoma	660	Pembrolizumab + lenvatinib vs. pembrolizumab	First-line	International
NCT03955354	II	Acral melanoma	30	SHR‐1210+ apatinib	First-line	China
NCT03991975	I, II	Metastatic and acral melanoma	42	TQB2450 + anlotinib	Second- or later-line	China
NCT04331093	II	Acral melanoma	40	SHR-1210+ apatinib	Neoadjuvant	China
NCT04277663	III	Acral melanoma	300	IBI310+ IBI308 vs IBI308 vs HDI	Adjuvant	China
NCT04397770	II	Acral melanoma	40	SHR-1210+apatinib+ temozolomide	First-line	China
NCT03602547	II	Mucosal melanoma	40	Toripalimab+CM082	First-line	China
NCT03241186	II	Mucosal melanoma	36	Ipilimumab+nivolumab	Adjuvant	US
NCT03986515	II	Mucosal melanoma	40	Apatinib+SHR-1210	Second- or later-line	China
NCT04622566	II	Mucosal melanoma	26	Pembrolizumab+lenvatinib	Adjuvant	China
NCT04462965	II	Mucosal melanoma	294	Toripalimab+temozolomide	Adjuvant	China
NCT04318717	I, II	Mucosal melanoma of head and neck	16	Pembrolizumab+ hypofractionated radiotherapy	Adjuvant	US
NCT04180995	II	Mucosal melanoma	30	Toripalimab, axitinib	Neoadjuvant	China
NCT04091217	II	Locally advanced or metastatic mucosal melanoma	43	Atezolizumab+bevacizumab	First- or later line	China
NCT03941795	II	Metastatic mucosal melanoma	99	Toripalimab+axitinib	First-line	China
NCT02978443	II	Metastatic acral and mucosal melanoma	14	Nivolumab+ipilimumab	First- or later line	US
NCT04653038	I	Unresectable, recurrent, or metastatic acral and mucosal melanoma	160	MGD013 (tebotelimab)	Second- or later-line	China